At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 475 enrolled
Drug / intervention
CT-P6 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination With Paclitaxel, in Patients With Metastatic Breast Cancer
In Brief
A Phase 3 clinical trial evaluating CT-P6, Herceptin, and 1 other intervention for Metastatic Breast Cancer. Completed, enrolled 475 participants across 1 site.
Detailed Summary
The purpose of the study is to demonstrate equivalence
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesSouth Korea
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2010
Enrollment StartJun 2010
Primary CompletionJul 2012
Study CompletionMar 2015
TodayJul 2026
First PostedMar 11, 2010
Enrollment StartJun 1, 2010
Primary CompletionJul 1, 2012
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.3 years ago
Interventions
CT-P6drug
Administered every 3 weeks
Herceptindrug
Administered every 3 weeks
Paclitaxeldrug
Administered every 3 weeks